Major Depressive Disorder - Pipeline Review, H1 2016

  • ID: 3720449
  • Drug Pipelines
  • 224 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Alkermes Plc
  • Cerecor Inc.
  • GlaxoSmithKline Plc
  • Luye Pharma Group Ltd.
  • Neuralstem, Inc.
  • Saniona AB
  • MORE
Major Depressive Disorder - Pipeline Review, H1 2016

Summary

‘Major Depressive Disorder - Pipeline Review, H1 2016’, provides an overview of the Major Depressive Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder
- The report reviews pipeline therapeutics for Major Depressive Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Major Depressive Disorder therapeutics and enlists all their major and minor projects
- The report assesses Major Depressive Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Major Depressive Disorder

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alkermes Plc
  • Cerecor Inc.
  • GlaxoSmithKline Plc
  • Luye Pharma Group Ltd.
  • Neuralstem, Inc.
  • Saniona AB
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Major Depressive Disorder Overview

Therapeutics Development

Pipeline Products for Major Depressive Disorder – Overview

Pipeline Products for Major Depressive Disorder – Comparative Analysis

Major Depressive Disorder – Therapeutics under Development by Companies

Major Depressive Disorder – Therapeutics under Investigation by Universities/Institutes

Major Depressive Disorder – Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Major Depressive Disorder – Products under Development by Companies

Major Depressive Disorder – Products under Investigation by Universities/Institutes

Major Depressive Disorder – Companies Involved in Therapeutics Development

Aequus Pharmaceuticals Inc.

Alkermes Plc

Allergan Plc

Angelini Group

Azevan Pharmaceuticals, Inc.

BioCrea GmbH

Bristol-Myers Squibb Company

Cerecor Inc.

e-Therapeutics Plc

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

H. Lundbeck A/S

Hua Medicine Ltd.

Intra-Cellular Therapies, Inc.

Johnson & Johnson

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Luye Pharma Group Ltd.

Mapreg S.A.S.

Methylation Sciences Inc.

miCure Therapeutics Ltd.

Mitsubishi Tanabe Pharma Corporation

Neuralstem, Inc.

nLife Therapeutics, S.L.

Otsuka Holdings Co., Ltd.

Pherin Pharmaceuticals, Inc.

Reviva Pharmaceuticals Inc.

Richter Gedeon Nyrt.

Saniona AB

Sumitomo Dainippon Pharma Co., Ltd.

Suven Life Sciences Ltd.

Takeda Pharmaceutical Company Limited

TRImaran Pharma, Inc.

Turing Pharmaceuticals AG

VistaGen Therapeutics , Inc.

Major Depressive Disorder – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(aripiprazole + sertraline) - Drug Profile

(buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile

AAD-2004 - Drug Profile

ALKS-7119 - Drug Profile

AN-788 - Drug Profile

aripiprazole - Drug Profile

AV-101 - Drug Profile

AVP-786 - Drug Profile

basimglurant - Drug Profile

BLI-1005 - Drug Profile

brexpiprazole - Drug Profile

bupropion hydrochloride ER - Drug Profile

cariprazine - Drug Profile

CB-2202 - Drug Profile

CERC-301 - Drug Profile

CERC-501 - Drug Profile

D-473 - Drug Profile

edivoxetine hydrochloride - Drug Profile

esketamine hydrochloride - Drug Profile

gepirone hydrochloride ER - Drug Profile

ITI-007 - Drug Profile

JNJ-42847922 - Drug Profile

ketamine hydrochloride - Drug Profile

lurasidone hydrochloride - Drug Profile

LY-03005 - Drug Profile

MAP-4343 - Drug Profile

MIN-117 - Drug Profile

miR-135 - Drug Profile

MSI-195 - Drug Profile

NLF-NEU - Drug Profile

NP-11948 - Drug Profile

NRX-1074 - Drug Profile

NSI-189 - Drug Profile

onabotulinumtoxin A - Drug Profile

PH-10 - Drug Profile

rapastinel - Drug Profile

RP-5063 - Drug Profile

S-47445 - Drug Profile

sirukumab - Drug Profile

Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder - Drug Profile

Small Molecule to Target SLC6A15 for Major Depressive Disorder - Drug Profile

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile

Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile

SNA-1 - Drug Profile

SRX-246 - Drug Profile

SUVN-911 - Drug Profile

TAK-653 - Drug Profile

tramadol hydrochloride - Drug Profile

trazodone hydrochloride - Drug Profile

vortioxetine hydrobromide - Drug Profile

VU-0431316 - Drug Profile

Major Depressive Disorder – Recent Pipeline Updates

Major Depressive Disorder - Dormant Projects

Major Depressive Disorder – Discontinued Products

Major Depressive Disorder – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Major Depressive Disorder, H1 2016

Number of Products under Development for Major Depressive Disorder – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2016

Major Depressive Disorder – Pipeline by Aequus Pharmaceuticals Inc., H1 2016

Major Depressive Disorder – Pipeline by Alkermes Plc, H1 2016

Major Depressive Disorder – Pipeline by Allergan Plc, H1 2016

Major Depressive Disorder – Pipeline by Angelini Group, H1 2016

Major Depressive Disorder – Pipeline by Azevan Pharmaceuticals, Inc., H1 2016

Major Depressive Disorder – Pipeline by BioCrea GmbH, H1 2016

Major Depressive Disorder – Pipeline by Bristol-Myers Squibb Company, H1 2016

Major Depressive Disorder – Pipeline by Cerecor Inc., H1 2016

Major Depressive Disorder – Pipeline by e-Therapeutics Plc, H1 2016

Major Depressive Disorder – Pipeline by Eli Lilly and Company, H1 2016

Major Depressive Disorder – Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Major Depressive Disorder – Pipeline by GlaxoSmithKline Plc, H1 2016

Major Depressive Disorder – Pipeline by H. Lundbeck A/S, H1 2016

Major Depressive Disorder – Pipeline by Hua Medicine Ltd., H1 2016

Major Depressive Disorder – Pipeline by Intra-Cellular Therapies, Inc., H1 2016

Major Depressive Disorder – Pipeline by Johnson & Johnson, H1 2016

Major Depressive Disorder – Pipeline by Lead Discovery Center GmbH, H1 2016

Major Depressive Disorder – Pipeline by Les Laboratoires Servier SAS, H1 2016

Major Depressive Disorder – Pipeline by Luye Pharma Group Ltd., H1 2016

Major Depressive Disorder – Pipeline by Mapreg S.A.S., H1 2016

Major Depressive Disorder – Pipeline by Methylation Sciences Inc., H1 2016

Major Depressive Disorder – Pipeline by miCure Therapeutics Ltd., H1 2016

Major Depressive Disorder – Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016

Major Depressive Disorder – Pipeline by Neuralstem, Inc., H1 2016

Major Depressive Disorder – Pipeline by nLife Therapeutics, S.L., H1 2016

Major Depressive Disorder – Pipeline by Otsuka Holdings Co., Ltd., H1 2016

Major Depressive Disorder – Pipeline by Pherin Pharmaceuticals, Inc., H1 2016

Major Depressive Disorder – Pipeline by Reviva Pharmaceuticals Inc., H1 2016

Major Depressive Disorder – Pipeline by Richter Gedeon Nyrt., H1 2016

Major Depressive Disorder – Pipeline by Saniona AB, H1 2016

Major Depressive Disorder – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016

Major Depressive Disorder – Pipeline by Suven Life Sciences Ltd., H1 2016

Major Depressive Disorder – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Major Depressive Disorder – Pipeline by TRImaran Pharma, Inc., H1 2016

Major Depressive Disorder – Pipeline by Turing Pharmaceuticals AG , H1 2016

Major Depressive Disorder – Pipeline by VistaGen Therapeutics , Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Major Depressive Disorder Therapeutics – Recent Pipeline Updates, H1 2016

Major Depressive Disorder – Dormant Projects, H1 2016

Major Depressive Disorder – Dormant Projects (Contd..1), H1 2016

Major Depressive Disorder – Dormant Projects (Contd..2), H1 2016

Major Depressive Disorder – Dormant Projects (Contd..3), H1 2016

Major Depressive Disorder – Dormant Projects (Contd..4), H1 2016

Major Depressive Disorder – Dormant Projects (Contd..5), H1 2016

Major Depressive Disorder – Dormant Projects (Contd..6), H1 2016

Major Depressive Disorder – Discontinued Products, H1 2016

Major Depressive Disorder – Discontinued Products (Contd..1), H1 2016

Major Depressive Disorder – Discontinued Products (Contd..2), H1 2016

List of Figures

Number of Products under Development for Major Depressive Disorder, H1 2016

Number of Products under Development for Major Depressive Disorder – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Aequus Pharmaceuticals Inc.
Alkermes Plc
Allergan Plc
Angelini Group
Azevan Pharmaceuticals, Inc.
BioCrea GmbH
Bristol-Myers Squibb Company
Cerecor Inc.
e-Therapeutics Plc
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
H. Lundbeck A/S
Hua Medicine Ltd.
Intra-Cellular Therapies, Inc.
Johnson & Johnson
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Luye Pharma Group Ltd.
Mapreg S.A.S.
Methylation Sciences Inc.
miCure Therapeutics Ltd.
Mitsubishi Tanabe Pharma Corporation
Neuralstem, Inc.
nLife Therapeutics, S.L.
Otsuka Holdings Co., Ltd.
Pherin Pharmaceuticals, Inc.
Reviva Pharmaceuticals Inc.
Richter Gedeon Nyrt.
Saniona AB
Sumitomo Dainippon Pharma Co., Ltd.
Suven Life Sciences Ltd.
Takeda Pharmaceutical Company Limited
TRImaran Pharma, Inc.
Turing Pharmaceuticals AG
VistaGen Therapeutics , Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll